RESEARCH TRIANGLE PARK, N.C., Feb. 19 /PRNewswire/ -- Mardil Inc., a cardiac medical device company with novel technology for treating mitral valve regurgitation, today announced the appointment of Daniel A. Pelak to its board of directors.
Mr. Pelak's significant experience in the field of cardiac medical devices will serve as a guiding force for Mardil, a company that has rapidly advanced its unique device from the development stage to human trials within a span of 2 years, according to Gopal Muppirala, CEO and co-founder of Mardil.
"Dan has a long history as a senior executive in the medical device industry, garnering multiple successes in growing young companies and managing corporate operating divisions," said Jai Ramon, M.D., Mardil co-founder and professor of surgery and director of adult cardiac surgery and cardiothoracic surgical research at the
The Mardil device, called BACE (basal annuloplasty of the cardia externally), began first-in-human testing in India last month, and clinical trials will expand internationally in the third quarter of 2009. The BACE device serves as a tension band that encircles the heart and supports the exterior heart muscle. Its gentle pressure enables the leaflets of the mitral valve to open and close properly and thus prevents the backflow of blood into the left ventricle, a condition called mitral regurgitation. The device is designed to be less invasive, less costly, and to reduce side effects and mortality rates associated with current mitral valve repair and replacement techniques.
"The BACE device is truly a breakthrough technology that has the potential to change the way we treat heart valve disease," Pelak said. "I am excited to be affiliated with a company that has successfu
|SOURCE Mardil Inc.|
Copyright©2009 PR Newswire.
All rights reserved